These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21417858)

  • 1. New drug therapies in peripheral T-cell lymphoma.
    Howman RA; Prince HM
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):457-72. PubMed ID: 21417858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
    Cheson BD
    Curr Opin Hematol; 2009 Jul; 16(4):299-305. PubMed ID: 19367159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of T-cell malignancies: current perspectives, key issues, and emerging therapies.
    Cheson BD
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S3-7. PubMed ID: 18086345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.
    Foss FM
    Expert Opin Drug Metab Toxicol; 2011 Sep; 7(9):1141-52. PubMed ID: 21726160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors in lymphoma.
    Copeland A; Buglio D; Younes A
    Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapies for cutaneous T-cell lymphomas.
    Horwitz SM
    Clin Lymphoma Myeloma; 2008 Dec; 8 Suppl 5():S187-92. PubMed ID: 19073526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pralatrexate (Folotyn).
    Abramovits W; Oquendo M; Granowski P; Gupta A; Cather J
    Skinmed; 2012; 10(4):244-6. PubMed ID: 23008944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies for peripheral T-cell lymphomas.
    Foss FM
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential of pralatrexate as a treatment of peripheral T-cell lymphoma.
    Dondi A; Bari A; Pozzi S; Ferri P; Sacchi S
    Expert Opin Investig Drugs; 2014 May; 23(5):711-8. PubMed ID: 24661228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.
    Shimanovsky A; Dasanu CA
    Expert Opin Pharmacother; 2013 Mar; 14(4):515-23. PubMed ID: 23409799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pralatrexate: an emerging new agent with activity in T-cell lymphomas.
    O'Connor OA
    Curr Opin Oncol; 2006 Nov; 18(6):591-7. PubMed ID: 16988580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of advanced-stage peripheral T-cell lymphomas.
    Kimby E
    Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
    Tobinai K
    Semin Hematol; 2010 Apr; 47 Suppl 1():S5-7. PubMed ID: 20359583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of new agents for peripheral T-cell lymphoma.
    Ito Y; Makita S; Tobinai K
    Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
    O'Connor OA; Hamlin P
    Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness.
    Armitage JO; Hsi ED; Foss FM
    Clin Adv Hematol Oncol; 2010 Dec; 8(12 Suppl 22):1-15. PubMed ID: 21491667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.